Piper Sandler Reiterates Neutral on Amphastar Pharma, Lowers Price Target to $21

Benzinga Newsdesk www.benzinga.com Negative 85.9%

Neg 85.9% Neu 0% Pos 0%

Piper Sandler analyst David Amsellem reiterates Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target from $25 to $21.